Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.
TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...
Tartarus is a Terra world generation pack for Minecraft Java v1.19 that adds 12 custom biomes to the Nether! This includes vanilla biomes, however these biomes have been reworked to fit the scheme of ...
UCB will advance its anti-tau antibody for Alzheimer’s disease solo after Roche and Genentech walked away from the asset known as bepranemab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback